Trials / Completed
CompletedNCT03380390
Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea
Multicenter, Open-Label, Interventional Study on the Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Subjects With Rosacea
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- Aclaris Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and tolerability of oxymetazoline HCl cream 1.0% when used as an adjunctive treatment to energy-based therapy for participants with moderate to severe persistent facial erythema associated with rosacea.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oxymetazoline HCL 1.0% Cream | Oxymetazoline HCl cream 1.0% once daily application |
| DEVICE | Energy-Based Therapy | Energy-based therapies (Potassium Titanyl Phosphate \[KTP\], Pulsed Dye Laser \[PDL\], or Intense Pulsed Light \[IPL\]) |
Timeline
- Start date
- 2017-12-04
- Primary completion
- 2018-06-15
- Completion
- 2018-06-15
- First posted
- 2017-12-21
- Last updated
- 2019-09-04
- Results posted
- 2019-06-28
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT03380390. Inclusion in this directory is not an endorsement.